Morgan Stanley lowered the firm’s price target on Vertex (VERX) to $55 from $60 and keeps an Overweight rating on the shares. The firm is ...

Reshma is the kind of leader who can deliver that extraordinary future—it only seems crazy because no one’s done it before. I ...

Vertex Pharmaceuticals has grown from a $7.5 billion market cap to over $120 billion as it’s commercialized several products.

BOSTON, April 07, 2025--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its first quarter 2025 financial results on Monday, May 5, 2025 after the financial markets ...

GreensKeeper Asset Management, an investment management company, released its first quarter 2025 investor letter. A copy of ...

DA Davidson lowered the firm’s price target on Vertex (VERX) to $50 from $55 and keeps a Buy rating on the shares as part of a broader research ...

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its first quarter 2025 financial results on Monday, May 5, ...